Shenyang Xingqi Pharmaceutical (300573.CH)-Looking Forward to a Leap in Valuation and Rich Dividends
Xingqi's newly approved atropine eye drops will drive high growth/valuation expansion due to sales exclusivity period.Together with lucrative...
662 Views
Lepu Biopharma (ä¹ę®ēē©ē§ę) IPO: Sentiment Cooled Down
Downsized deal amid cooled sentiment for Chapter 18A, we think the valuation of Lepu Biopharm is not attractive for investors.
474 Views
Zhaoke Ophthalmic (å ē§ē¼ē§) IPO Trading: Strong Cornerstone Doesn't Save the Deal
We re-iterate our differentiated bearish view with the deal. The deal received lukewarm interests from retail and institutional investors. We would...
518 Views
Zhaoke Opthalmology IPO Valuation: Overpriced
Some of the companyās drug candidates have the potential to become market-leading products, however, Zhaoke does not have any prior experience in...
483 Views
ECM Weekly (18th April 2021) - ByteDance Zhaoke, We Doctor, Medlive, Bio-Thera, Grab, Ngern Tid Lor
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
589 Views